RECURRENT ENDOMETRIAL CARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with endometrial cancer that had returned or spread. The goal was to see if the combination could slow or stop cancer growth. Participants had already tried other treatments and their cancer ha…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:56 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without their cancer getting worse. About 813 participants with stage III, IV, or recu…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:54 UTC
-
Engineered virus targets Hard-to-Treat endometrial cancer in early trial
Disease control OngoingThis early-phase trial tests a specially designed virus that may selectively attack cancer cells while sparing healthy ones. The study includes up to 34 people with advanced or recurrent endometrial cancer. The main goal is to find the safest dose and understand side effects, wit…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 06:48 UTC
-
New drug combo targets recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in people whose endometrial, ovarian, peritoneal, or fallopian tube cancer has returned. The main goal is to find the safest dose and understand side effects. About 31 particip…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
New Triple-Drug cocktail shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated May 26, 2026 06:45 UTC
-
New drug combo shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New drug combo shows promise for hard-to-treat endometrial cancer
Disease control OngoingThis study tests whether adding a third drug (ribociclib) to a two-drug combination (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. The trial involves 90 participants and aims to see if the three-drug combo can shrink tumors or st…
Matched conditions: RECURRENT ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC